NEW YORK, January 17, 2017 /PRNewswire/ --
This morning, Stock-Callers.com reassesses the performances of Exact Sciences Corp. (NASDAQ: EXAS), Agilent Technologies Inc. (NYSE: A), HealthSouth Corp. (NYSE: HLS), and MEDNAX Inc. (NYSE: MD). These companies are part of the Healthcare sector, which has received a "Market Perform" rating from Charles Schwab on January 12th, 2017 due to positives such as fair to slightly below-average valuations, solid balance sheets, generally good dividend yields, improved overall cost structure, and rising demand for health care products and services. These stocks research reports can be downloaded now by simply registering for free at:
Shares in Madison, Wisconsin headquartered Exact Sciences Corp. ended Friday's session 0.16% lower at $19.04. A total volume of 3.37 million shares was traded, which was above their three months average volume of 2.68 million shares. The stock has advanced 37.18% in the last month, 2.70% over the previous three months, and 42.51% on an YTD basis. The Company's shares are trading 25.61% above their 50-day moving average and 37.69% above their 200-day moving average. Moreover, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers, have a Relative Strength Index (RSI) of 72.26.
On January 13th, 2017, Exact Sciences announced that it granted restricted stock units covering a total of 53,275 shares of common stock to 45 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. Your complete research report on EXAS can be retrieved for free at:
Santa Clara, California headquartered Agilent Technologies Inc.'s shares rose 0.35%, closing the day at $48.69. A total volume of 1.57 million shares was traded. The stock has advanced 5.26% in the last month, 8.13% over the previous three months, and 6.87% since the start of this year. The Company's shares are trading 6.81% and 8.42% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have an RSI of 64.43.
On December 21st, 2016, Agilent Technologies announced that the Analytical Scientist has ranked the Agilent Intuvo 9000 Gas Chromatograph System No. 1 on its list of 2016's best innovations. The publication, which specializes in analytical chemistry, praised the Intuvo for its highly advanced temperature control, leak-free connections and innovative column design.
On January 04th, 2017, research firm Barclays upgraded the Company's stock rating from 'Equal Weight' to 'Overweight' while revising its previous target price from $48 a share to $51 a share. A free report is just a click away at:
Last Friday, shares in Birmingham, Alabama headquartered HealthSouth Corp. gained 0.70%, closing the session at $41.79. The stock recorded a trading volume of 1.41 million shares. The Company's shares have advanced 0.94% in the last one month, 3.37% over the previous three months, and 1.33% on an YTD basis. The stock is trading 1.96% above its 50-day moving average and 4.83% above its 200-day moving average. Furthermore, shares of HealthSouth, which owns and operates inpatient rehabilitation hospitals, home health agencies, and hospice agencies in the US, have an RSI of 55.84.
On January 04th, 2017, research firm Piper Jaffray initiated a 'Neutral' rating on the Company's stock.
On January 10th, 2017, HealthSouth and Memorial Hospital at Gulfport announced they have entered into a joint venture to own and operate an existing 33-bed physical rehabilitation unit at Memorial Hospital at Gulfport. The inpatient rehabilitation hospital will remain in its current location at 4500 13th St. in Gulfport, Mississippi. There will be no interruption to care provided to patients. The hospital will continue to serve patients who have experienced stroke, trauma, brain and orthopedic injuries and other major illnesses or injuries. Sign up for your complimentary research report on HLS at:
Sunrise, Florida-based MEDNAX Inc.'s stock finished the session 0.76% higher at $70.69, with a total trading volume of 367,967 shares. The Company's shares have advanced 6.91% in the last month, 6.85% in the previous three months, and 6.05% on YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.95% and 4.79%, respectively. Additionally, shares of MEDNAX, which together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the US and Puerto Rico, have an RSI of 70.47. Register for free on Stock-Callers.com and download the latest research report on MD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA